NSU Newsroom

SharkBytes

Horizons

This version of NSU News has been archived as of February 28, 2019. To search through archived articles, visit nova.edu/search. To access the new version of NSU News, visit news.nova.edu.

This version of SharkBytes has been archived as of February 28, 2019. To search through archived articles, visit nova.edu/search. To access the new version of SharkBytes, visit sharkbytes.nova.edu.

News Releases Archive

Contact

Division of Public Relations and Marketing Communications
Nova Southeastern University
3301 College Avenue
Fort Lauderdale, Florida 33314-7796

nova.edu/prmc

SharkBytes Archives

Contact

Division of Public Relations and Marketing Communications
Nova Southeastern University
3301 College Avenue
Fort Lauderdale, Florida 33314-7796

(954) 262-5353
(800) 541-6682 x25353
Fax: (954) 262-3954
communications@nova.edu

NSU Researcher Makes Breakthrough Discovery to Curb Heart Failure

FT. LAUDERDALE-DAVIE Fla. —-  A Nova Southeastern University (NSU) researcher has announced a breakthrough discovery to block a protein that can contribute to heart failure.

His discovery will appear in an upcoming issue of the prestigious medical journal, the Journal of the American College of Cardiology.

Anastasios Lymperopoulos, Ph.D., an NSU College of Pharmacy assistant professor of pharmacology, has discovered a novel method, using gene therapy, to block the actions of a gene-encoded protein.

That protein, known as beta-arrestin 1, causes an increase of aldosterone production from the body’s adrenal glands into the blood. Aldosterone is a hormone. It increases the reabsorption of sodium and water into the kidneys, causing high blood volume and blood pressure. It also has several direct damaging effects on the heart, such as fibrosis, hypertrophy, and inflammation.

An increase in blood volume causes high blood pressure. This in turn decreases the pumping action of the heart, and is one of the causes of heart failure.

By finding a way to block beta-arrestin 1 through this gene therapy approach, professor Lymperopoulos hopes it will lead to the reduction of the severity of heart failure. He is now testing new and existing heart failure medications such as Cozaar, Diovan and Atacand, to see how effective they are at blocking this damaging effect of beta-arrestin on the heart.

Lymperopoulos receives funding from the American Heart Association through a Scientist Development Grant for his research at NSU.

Media Contact:
Ken Ma, NSU Office of Public Affairs
954-262-5408 (office), 954-830-4177 (cell), ken.ma@nova.edu